Coriolis Pharma Opens New ATMP Formulation Development Facilities

Coriolis’ new ATMP facilities will meet the growing demand for formulation development and analytical characterization for ATMPs up to BSL2/S2 level and increase Coriolis’ capabilities significantly.

MARTINSRIED-MUNICH, Germany, February 01, 2022 / B3C newswire / -- Coriolis Pharma, a globally operating service provider and one of the world leaders in formulation research and development of biopharmaceuticals and vaccines, today announced the opening of its new ATMP development facilities under biosafety level S2 (BSL2 / S2).

After one year of re-construction, the new facilities in close proximity to Coriolis’ headquarters in Martinsried will significantly increase Coriolis’ capabilites for ATMP development. Formulation development for ATMPs, including cell culture activities, particle characterization, particle identification and forensic, analytical ultracentrifugation and a lyophilization development center will be available all under biosafety level 2, for Coriolis’ clients and partners.

“The new location with innovative labs and offices will be able to accommodate in the future more than 100 scientific employees,” said Dr. Michael Wiggenhorn, CEO of Coriolis Pharma.” With this expansion, we will meet the increasing demand for formulation development and analytical characterization of ATMPs.”

Advanced therapy medicinal products (ATMPs) are booming, but ATMP formulations are still far from advanced. Similar to mRNA vaccines, ATMPs either have a very short shelf life (hours to days) or require (ultra) cold storage conditions. A tailored formulation development program, also exploring lyophilization as an option, can remarkably improve this situation.

Already in 2018, Coriolis started strengthening its scientific expertise and services for ATMPs with a dedicated formulation unit for ATMPs and scientific collaborations that resulted in several peer-reviewed scientific publications. The opening of the new facilities marks the next step in the organic growth of the company.

“Having all our S2 activities in a dedicated and tailored facility increases the efficiency of our work procedures and creates a knowledge-hub for our ATMP projects,” explained Dr. Gerhard Sax, Business Unit Manager ATMP. “But what excites me the most is that we now have enough space to test and implement even more new and emerging technologies right under S2.”

Caption: Inside the new ATMP facilities of Coriolis Pharma in Martinsried-Munich
For high resolution please click the image.

About Coriolis Pharma
Coriolis Pharma is a globally operating service provider and one of the world leaders in formulation research and development of biopharmaceutical drugs including proteins, peptides, monoclonal antibodies, nucleic acids, virus-like particles, vaccines, advance therapy medicinal products (ATMPs) and genetically modified organisms (GMOs). Coriolis Pharma develops liquid and lyophilized formulations with all technologies and analytical methods in-house. For each individual project, highly skilled scientists develop tailor-made study designs that align with the clients’ drug development strategy. With science-driven innovative solutions, Coriolis Pharma supports all phases of drug development including troubleshooting, batch-release testing including innovative methods and formulation optimization even beyond market approval. Coriolis Pharma’s mission is: formulating innovation!

Contact

Coriolis Pharma Research GmbH
Dr. Daniel Weinbuch
Scientific Marketing Specialist
+49 (0) 89 4177 60 – 149
daniel.weinbuch@coriolis-pharma.com
Fraunhoferstr. 18b
82152 Martinsried-Munich
Germany

Keywords: Laboratories; Facility Design and Construction; Research; Drug Compounding; Freeze Drying; ultracentrifugation; Drug Therapy; Research; Pharmaceutical Preparations; Germany

Published by B3C newswire